A Boston-based biotech company called Pieris Pharmaceuticals announced it’s been selected to receive a $14.2 million euro ($17 million USD) grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy for the research and development of a proprietary, oral inhaled Anticalin protein targeting connective tissue growth factor (CTGF) also known as CCN2. Known as PRS-220, the study in the southern German state centers on the investigation of the use of the novel investigational product for post-acute sequelae of SARS-CoV-2 infection (PASC) pulmonary fibrosis (PASC-PF), also known as post-COVID-19 syndrome pulmonary fibrosis or “long COVID.” This study, plus the development of the investigational product in clinical trials addressing idiopathic pulmonary fibrosis (IPF), commences in 2022. Positioning itself as a pioneer in the inhaled biologics space,” the company seeks to leverage their respiratory platform to improve patients fighting diseases such as IPF and COVID-19.
TrialSite provides a breakdown of this investigational drug and the new study for the Community.
What is idiopathic pulmonary fibrosis or IPF?
Idiopathic pulmonary fibrosis (I...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).